Our history
Today, our history is more than just a timeline — it’s a testament to our vision of transforming lives through science and innovation.
This is the first high-tech pharmaceutical manufacture in Azerbaijan to manage the full-cycle production of solid dosage forms, supported by strong research and development (R&D) capabilities.
Scandens Pharmaceutical Industries Ltd was founded in 2016 as the first pharmaceutical plant in Azerbaijan with a fully integrated production cycle.
The construction of the facility began in 2017 and was rapidly developed in accordance with modern technologies and international requirements. Equipped with advanced machinery from world renowned companies such as Bosh - Syntegon, Uhlmann, Fette, Glatt, FläktGroup, and Stilmass, the plant achieved full compliance with EU GMP standards.
From the outset, production processes were established in three key areas: solid dosage forms, semi-solid and suppositories, and sterile products. Initially, the manufacturing of more than 90 types of solid dosage medicines was planned, with further expansion into antibiotics and oncology drugs in the near future.
A milestone was reached in 2023 when Scandens signed a strategic cooperation agreement with Hungary’s Gedeon Richter, a pharmaceutical company with 125 years of tradition. This agreement paved the way for the local production of both original and generic medicines of Gedeon Richter at the Scandens facility.
The company has also fostered strong educational partnerships, particularly with the University of Pécs and Pannon Pharma, creating training and internship programs for Azerbaijani students, while supporting joint practical opportunities with local universities.
In May 2025, Scandens, with the support of the Ministry of Health of Azerbaijan and the Embassy of Hungary in Baku, organized the international event “Azerbaijan Pharmaceutical Industry: Past, Present, and Future” at the Heydar Aliyev Center. The event emphasized strengthening domestic production, promoting innovation driven growth, and expanding international collaboration.
Today, Scandens stands at the forefront of Azerbaijan’s pharmaceutical industry, having entered the production phase with plans to significantly expand its portfolio, thereby continuing to contribute sustainably to the nation’s healthcare system and global partnerships.
2024
03 october 2024
Announced a major breakthrough in mRNA vaccine technology for combating emerging pandemics,
showcasing
significant advancements in rapid vaccine development and global distribution strategies.
16 November 2024
The company, initially called "WellHealth Laboratories," was founded in Zurich, Switzerland, by Dr.
Emil Hauser, focusing on herbal remedies and natural health products.
28 December 2024
Released its first synthetic drug, "CardioRelief," for treating heart conditions, which became a
global success and solidified its reputation as a reliable pharmaceutical brand.
2021
03 october 2024
Received FDA approval for "NeuroFlex," a revolutionary drug for managing early-stage Alzheimer’s
disease, offering patients hope for slowing cognitive decline and improving quality of life.
16 November 2024
Renamed to "Hauser Pharmaceuticals" to reflect its broader mission in modern medicine, symbolizing
its
transition from herbal remedies to a global pharmaceutical leader.
28 December 2024
Opened its first manufacturing plant in the United States to meet growing demand, marking a
significant milestone in its expansion strategy and operational capabilities.
28 December 2024
Expanded into cancer research, establishing a dedicated oncology division and making substantial
progress in developing innovative treatments for various types of cancer.
2016
03 october 2024
Ranked among the top 10 pharmaceutical companies worldwide based on revenue, driven by consistent
innovation, a strong research pipeline, and an expanding global footprint.
16 November 2024
Launched a global initiative for affordable access to essential medicines in developing countries,
providing life-saving drugs to millions and earning recognition for corporate social responsibility.
2010
03 october 2024
Launched a global initiative for affordable access to essential medicines in developing countries,
providing life-saving drugs to millions and earning recognition for corporate social responsibility.
16 November 2024
Developed and patented "ImmunoPro," a groundbreaking vaccine for a rare autoimmune disorder,
becoming
a pioneer in addressing unmet medical needs for niche diseases.
28 December 2024
Acquired BioGenix, a biotechnology company specializing in gene therapy research, paving the way for
cutting-edge treatments and expanding its research capabilities.
2003
03 october 2024
Lorem ipsum dolor sit amet, consectetur adipisicing elit. At consequuntur delectus explicabo labore
nihil officia optio repudiandae similique soluta! Aliquam corporis cum delectus inventore. Debitis
laborum libero nesciunt quisquam repellendus.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. At consequuntur delectus explicabo labore
nihil officia optio repudiandae similique soluta! Aliquam corporis cum delectus inventore. Debitis
laborum libero nesciunt quisquam repellendus.
Hokmali, Absheron District, Baku, AZ0115
Quick Links
Useful links
All rights reserved © 2026 Scandens LLC